Latvia moves to tighten drug safety
Starting on May 1, all medicines sold in Latvia will have to becategorized as either prescription or over-the-counter, and prescriptions will have to be held at pharmacies and drugstores after the drug is issued so that the State Pharmacy Inspectorate can check at any time if a prescription medicine has been sold without a prescription, as currently can be done.
An official at the Welfare Ministry's Pharmacy Department said the new regulations are aimed at improving the safe supply of drugs, to ensure people are not victims of incorrect and irrational use of prescription medicines, reports the LETA news agency.
The State Drug Agency says 4,730 drugs are registered in Latvia, of which 1,462 (31%) are OTCs. They include treatments for flu, sleeping disorders and diarrhea.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze